Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

Shaji Kumar(Mayo Clinic in Arizona), Jesús G. Berdeja(Sarah Cannon), Rubén Niesvizky(NewYork–Presbyterian Hospital), Sagar Lonial(Emory University), Jacob P. Laubach(Dana-Farber Cancer Institute), Mehdi Hamadani(West Virginia University), A. Keith Stewart(Mayo Clinic in Arizona), Parameswaran Hari(Medical College of Wisconsin), Vivek Roy(WinnMed), Robert Vescio(Cedars-Sinai Medical Center), Jonathan L. Kaufman(Emory University), Deborah Berg(Millennium Engineering and Integration (United States)), Eileen Liao(Takeda (United States)), Alessandra Di Bacco(Millennium Engineering and Integration (United States)), Jose Estevam(Takeda (United States)), Neeraj Gupta(Millennium Engineering and Integration (United States)), Ai-Min Hui(Takeda (United States)), S. Vincent Rajkumar(Mayo Clinic in Arizona), Paul G. Richardson(Dana-Farber Cancer Institute)
The Lancet Oncology
November 16, 2014
Cited by 264

Abstract


Related Papers

No related papers found

Powered by citation graph analysis